Recombinant protein · Agonist of growth hormone receptor (GHR) · developed by Pfizer Ireland Pharmaceuticals
Somatrogon is a long-acting human growth hormone analog that binds the growth hormone receptor and activates STAT5b signaling, increasing serum IGF-1 and promoting linear growth. It is being studied in pediatric growth hormone deficiency and related conditions.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 14, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02968004 | Phase 3 | Pediatric Growth Hormone Deficiency | Completed | OPK |
| NCT03810664 | Phase 1 | Healthy Male Volunteers | Completed | OPK |
| NCT01060722 | Phase 1 | Healthy | Completed | OPK |
| NCT06587035 | N/A | Dwarfism, Pituitary | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dwarfism, PituitaryHealthyHealthy Male VolunteersPediatric Growth Hormone Deficiency
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →